This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
by Zacks Equity Research
Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Alpha Cognition Inc. (ACOG) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
by Zacks Equity Research
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.
Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Astellas Pharma (ALPMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Astellas Pharma Inc. (ALPMY) and AngioDynamics (ANGO) have performed compared to their sector so far this year.
Should Value Investors Buy Astellas Pharma (ALPMY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Astellas Pharma (ALPMY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
New Strong Sell Stocks for October 2nd
by Zacks Equity Research
ALPMY, BTDPY and ALRS have been added to the Zacks Rank #5 (Strong Sell) List on October 2, 2023.
New Strong Sell Stocks for September 26th
by Zacks Equity Research
ALPMY, ASH and DHC have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2023.
New Strong Sell Stocks for September18th
by Zacks Equity Research
ALPMY, CBRE and FMAO have been added to the Zacks Rank #5 (Strong Sell) List on September 18, 2023.
New Strong Sell Stocks for August 21st
by Zacks Equity Research
ALPMY, CYRX and DRCT have been added to the Zacks Rank #5 (Strong Sell) List on August 21, 2023.
ALPMY or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALPMY vs. ZTS: Which Stock Is the Better Value Option?
New Strong Sell Stocks for June 22nd
by Zacks Equity Research
ALPMY, AKZOY, and AVVID have been added to the Zacks Rank #5 (Strong Sell) List on June 22, 2022.
Insights Into a Cloudy Q1 Earnings Season
by John Blank
Focus your mind. On fresh facts about the uncertainty.
A Q1 Earnings Primer: Global Week Ahead
by John Blank
The coming wave of Q1 earnings releases will be parsed for fresher signals of economic activity -- including forward guidance -- than tends to be available from conventional macro releases.
Astellas Acquires Xyphos to Boost Immuno-oncology Pipeline
by Zacks Equity Research
Astellas (ALPMY) acquires Xyphos and gains the latter's novel and proprietary ACCEL technology platform.
Why Did Pfizer (PFE) Stock Pop Today?
by Ryan McQueeney
Shares of Pfizer (PFE) and Astellas Pharma (ALPMY) moved higher in morning trading Thursday after the companies said their new prostate cancer drug, Xtandi, met the main goal of an important clinical trial.
Seattle Genetics Halts Phase III Study on Leukemia Drug
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) announced that it will discontinue the phase III study, CASCADE o vadastuximab talirine (SGN-CD33A) in frontline older acute myeloid leukemia (AML) patients.